# Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

> **NCT05585034** · PHASE1 · COMPLETED · sponsor: **Xencor, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Melanoma Excluding Uveal Melanoma
- Non-small Cell Lung Cancer, Squamous or Non-squamous
- Urothelial Carcinoma
- Renal Cell Carcinoma, Clear Cell
- Castration-resistant Prostate Cancer
- Ovarian Cancer, Epithelial
- TNBC - Triple-Negative Breast Cancer
- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** XmAb®808
- **BIOLOGICAL:** Keytruda® (pembrolizumab)

## Key facts

- **NCT ID:** NCT05585034
- **Lead sponsor:** Xencor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-14
- **Primary completion:** 2025-05-20
- **Final completion:** 2025-05-20
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05585034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05585034, "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05585034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*